Carnegie Investment Bank is proud to have acted as Joint Bookrunner in connection with SpinChip Diagnostics ASA’ NOK 145 million private placement.
The financing round was led by bioMérieux, a world leader in the field of in vitro diagnostics, with its NOK 115 million investment.
The proceeds from the financing round will be used to further advance SpinChip’s proprietary point-of care (POC) in vitro diagnostics platform, prepare for a CE mark in 2025, and for general corporate purposes.
Carnegie would like to congratulate SpinChip Diagnostics on the successfully completed private placement and are grateful for the vote of confidence.